Generic Drugmaker Hikma Pledges $1bn in US Investment

Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report

The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.

Generic drugmaker Hikma pledges $1bn in US investment

With tariffs looming, Indian drugmaker Hikma has said it will spend $1bn to expand its manufacturing and R&D operations in the US by 2030.

Hikma Commits $1 Billion to Boost US Drug Manufacturing and R&D Services by 2030

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient needs through domestic innovation and capacity.

Hikma to spend $1 billion to expand generic drug manufacturing and R&D in the U.S.

COLUMBUS, Ohio — In its ongoing mission to help meet America's growing need for high-quality U.S.-made medicines, Hikma Pharmaceuticals USA will invest $1 billion by 2030 to further expand its domestic manufacturing and R&D capabilities. This new phase of investment – America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma's well-established domestic capabilities to develop, produce and deliver a broad range…

Hikma pledges $1B to expand US manufacturing presence

Hikma Pharmaceuticals has promised to spend $1 billion on growing its US manufacturing and R&D footprint by 2030. The drugmaker said its latest investment — which it refers to as “America Leans on Hikma” — will strengthen ...